<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
   <channel>
      <title>RNAi News Current Issue</title>
      <link>http://www.rnainews.com/issues/index.html</link>
      <description></description>
      <language>en-us</language>
      <copyright>Copyright (c) 2008 GenomeWeb LLC. All rights Reserved.</copyright>
<managingEditor>editor@genomeweb.com</managingEditor>
      <webMaster>webmaster@iproduction.com</webMaster>
      <pubDate>Thu, 15 May 2008 19:56:59 GMT</pubDate>
      <lastBuildDate>Thu, 15 May 2008 19:56:59 GMT</lastBuildDate>
      <generator>IPS - www.iproduction.com</generator>

      <item>
         <title><![CDATA[MicroRNA Drugs Startup Miragen Nears Close of Series A, Begins Defining Pipeline]]></title>
         <description><![CDATA[While specific details of Miragen&#146;s planned pipeline are being kept under wraps, a company official said that the initial indication pursued would likely be heart failure, a condition one of the firm&#146;s co-founders has linked to several microRNAs.]]></description>
         <link>http://www.rnainews.com/issues/6_20/features/146941-1.html?CMP=OTC-RSS</link>
      </item>

      <item>
         <title><![CDATA[Nastech Confirms Change in Focus While Alnylam Addresses Partnering Concerns ]]></title>
         <description><![CDATA[Although Nastech had said in an SEC filing that it would refocus on RNAi, the company&#146;s CEO said that it would not continue developing non-RNAi programs after ongoing clinical trials are completed. Meanwhile, Alnylam&#146;s CEO said that the firm&#146;s track record of alliances speaks for itself.]]></description>
         <link>http://www.rnainews.com/issues/6_20/features/146942-1.html?CMP=OTC-RSS</link>
      </item>

      <item>
         <title><![CDATA[Harvard&#146;s Carl Novina Discusses Function Of microRNA and Their Role in Cancer]]></title>
         <description><![CDATA[Recently, Novina and colleagues published a paper suggesting that microRNAs repress the initiation of translation by preventing a specific ribosome component from joining to targeted mRNAs.]]></description>
         <link>http://www.rnainews.com/issues/6_20/rnainsider/146943-1.html?CMP=OTC-RSS</link>
      </item>

      <item>
         <title><![CDATA[USPTO Publishes One Patent, Four Patent Applications Related to RNAi]]></title>
         <description><![CDATA[]]></description>
         <link>http://www.rnainews.com/issues/6_20/ipupdate/146944-1.html?CMP=OTC-RSS</link>
      </item>

      <item>
         <title><![CDATA[Isis Pharmaceuticals, Novosome, Calando Pharmaceuticals]]></title>
         <description><![CDATA[]]></description>
         <link>http://www.rnainews.com/issues/6_20/strands/146945-1.html?CMP=OTC-RSS</link>
      </item>

      <item>
         <title><![CDATA[Asuragen, Oxford Gene Technology]]></title>
         <description><![CDATA[]]></description>
         <link>http://www.rnainews.com/issues/6_20/products_services/146946-1.html?CMP=OTC-RSS</link>
      </item>

      <item>
         <title><![CDATA[Thomas Haag, Mark Tilley, James Hamilton, Robert Brown]]></title>
         <description><![CDATA[]]></description>
         <link>http://www.rnainews.com/issues/6_20/peopleinthenews/146947-1.html?CMP=OTC-RSS</link>
      </item>
   </channel>
</rss>